Viral agent associated with mystery swine disease
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsDanny W. Chladek, David E. Gorcyca, Louis L. Harris
Life of this patent
Estimating the term…
Abstract
A substantially avirulent vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS) is provided, which effectively immunizes swine against the U.S. and European forms of the disease, together with a method of growing the viral agent in vitro, and a method of attenuating the virus for vaccine preparation.
Claims16
A vaccine composition comprising live porcine reproductive and respiratory syndrome (PRRS) virus in a modified form and mixed with a pharmacologically compatible carrier agent, said modified virus comprising ATCC-VR2332 virus passaged at least 70 times in cell culture such that when the modified virus is administered to a swine or other mammal prone to PRRS, it fails to cause clinical signs of PRRS disease but is capable of inducing an immune response that immunizes the mammal against pathogenic forms of PRRS.
A method of immunizing swine against porcine reproductive and respiratory syndrome (PRRS), said method comprising the step of administering to swine a vaccine composition including a live porcine reproductive and respiratory syndrome virus mixed with a pharmacologically compatible carrier agent, said virus comprising ATCC-VR2332 virus passaged at least 70 times in cell culture to modify the virus such that when the modified virus is administered to a swine or other mammal prone to PRRS, it fails to cause clinical signs of PRRS disease but is capable of inducing an immune response that immunizes the mammal against pathogenic forms of PRRS.
A method of producing commercial quantities of PRRS vaccine, comprising the steps of:
- preparing a production culture of a modified form of the ATCC-VR2332 virus, including the steps of passaging ATCC-VR2332 virus at least 70 times in cell culture to modify the virus such that when the modified virus is administered to a swine or other mammal prone to PRRS, it fails to cause clinical signs of PRRS disease but is capable of inducing an immune response that immunizes the mammal against pathogenic forms of PRRS, and generating a production culture from the modified ATCC-VR2332 virus;
- harvesting the production virus culture;
- adding a stabilizing agent to the production virus culture;
- and
- lyophilizing the production virus culture.
Dependencies are inferred from the claim text.